Cambridge, MA-based Biogen Idec (NASDAQ: [[ticker:BIIB]]) today announced that it has formed an alliance with a Swiss startup, Neurimmune Therapeutics, to develop antibody-based treatments for Alzheimer’s disease. Under the terms of the deal, Biogen could pay up to $380 million for candidate molecules, which it will be responsible for developing and commercializing. In an interview with Bob back in August, Biogen CEO Jim Mullen talked about how deals like these fit into Biogen’s overall innovation strategy.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
